SciClone Receives ZADAXIN(R) Marketing Approvals in Mexico & Cambodia Eight Approvals Now Received During 1998; Mexico is a Key Market

San Mateo, Calif. (ots-PRNewswire) - SciClone Pharmaceuticals (Nasdaq: SCLN) today reported that ZADAXIN thymosin alpha 1, the Company's lead product, has been approved in Mexico. The approval is for use of ZADAXIN as an influenza vaccine adjuvant and is expected to be expanded to include use for the treatment of hepatitis B and hepatitis C. Mexico is one of six additional key countries from which SciClone has been awaiting ZADAXIN marketing approval. The Company also reported that it recently received ZADAXIN marketing approval for the treatment of hepatitis B and hepatitis C in Cambodia.

"The Mexican approval is a key to profitability," said Donald Sellers, SciClone's President and Chief Executive Officer. "We believe the major use of ZADAXIN in Mexico will be for the treatment of hepatitis C, but our first job was to get the drug approved and into physicians' hands. Other keys to our near-term profitability are pending ZADAXIN marketing applications in Brazil, Egypt, India, Korea, Taiwan and Turkey."

ZADAXIN, an immune system enhancer, now is approved for the treatment of hepatitis B in Cambodia, People's Republic of China, Kuwait, Myanmar (formerly Burma), Peru, the Philippines and Singapore. It is approved for hepatitis C in Cambodia and the Philippines and as an influenza vaccine adjuvant in Argentina, Italy and Mexico. ZADAXIN hepatitis B marketing applications are pending in 21 additional countries. In Japan, Phase 3 studies in hepatitis B and Phase 2 studies in hepatitis C have been initiated by Schering-Plough KK, SciClone's exclusive partner. ZADAXIN has been used in combination with multiple brands of alpha interferon for the treatment of hepatitis C. The combination of ZADAXIN plus interferon has demonstrated improved efficacy over interferon alone without increasing interferon's toxicity. In addition, ZADAXIN has been safely combined and shown utility with both famciclovir and lamivudine in the treatment of chronic hepatitis B.

Hepatitis B and hepatitis C are highly infectious liver diseases that can lead to cirrhosis, liver cancer and death. Worldwide, there are an estimated 350 million carriers of hepatitis B and an estimated 170 million carriers of hepatitis C. The only established first line therapy for hepatitis B other than ZADAXIN is alpha interferon. The estimated worldwide sales of the various alpha interferon brands are over $1 billion. ZADAXIN, with no serious side effects seen in more than 2,000 clinical trial patients, is prescribed for hepatitis B as a safer single-agent therapy than the alpha interferons. ZADAXIN plus alpha interferon is used as a safer combination therapy for hepatitis C than alpha interferon plus other drugs.

SciClone Pharmaceuticals, Inc. is a global biopharmaceutical company that acquires, develops and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases, such as hepatitis B, hepatitis C, cystic fibrosis, cancer and immune system disorders. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company's Investor Relations Department at 800-724-2566. SciClone's common stock is listed on the Nasdaq National Market under the symbol SCLN.

The statements made in this press release contain certain forward looking statements that involve a number of risks and uncertainties, including statements regarding estimated future revenues. Actual events or results may materially differ from the Company's expectations. The Company's success in expanding ZADAXIN marketing approvals and increasing sales of ZADAXIN in foreign markets, future actions by the Food and Drug Administration or equivalent regulatory authorities in foreign countries, results of pending or future clinical trials, as well as the risk factors listed from time to time in the Company's SEC reports, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the Company.

ots Original Text Service: SciClone Pharmaceuticals
Internet: http://www.newsaktuell.de

Contact:

Shawn K. Singh
Senior Vice President of SciClone
(USA) 650-358-1451

Company News On-Call:
http://www.prnewswire.com/comp/775865.html or
Fax: (USA) 800-758-5804, ext. 775865

Web site: http://www.sciclone.com

*** OTS-ORIGINALTEXT UNTER AUSSCHLIESSLICHER INHALTLICHER

VERANTWORTUNG DES AUSSENDERS ***

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | PRN/08